LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference.
Date: Wednesday, January 11, 2023
Time: 10:30 a.m.-11:10 a.m. PST / 1:30 p.m.-2:10 p.m. EST
A webcast of the presentation can be accessed under the “Events” tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events. A replay will be archived for 90 days following the presentation date.
About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study ( NCT04887259 ). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling ( NCT05369000 ). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.
Argot Partners (IR/Media)